MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

7.53 -2.96

Buy Sell

Overview

Share price change

24h

Current

Min

7.52

Max

7.8

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	11.295 66.418
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-35.73% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-7.7M 351M
Previous open	10.49
Previous close	7.53

News Sentiment

By Acuity

50%

154 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 kwi 2026, 23:25 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 kwi 2026, 22:45 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 kwi 2026, 18:03 UTC

Earnings

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 kwi 2026, 23:58 UTC

Earnings

Review & Preview: Earnings Time -- Barrons.com

13 kwi 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 kwi 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 kwi 2026, 23:01 UTC

Earnings

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 kwi 2026, 23:01 UTC

Earnings

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 kwi 2026, 23:01 UTC

Earnings

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 kwi 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 kwi 2026, 21:26 UTC

Major News Events

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 kwi 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 kwi 2026, 21:16 UTC

Earnings

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

13 kwi 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 kwi 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 kwi 2026, 19:50 UTC

Market Talk

Major News Events

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 kwi 2026, 19:27 UTC

Market Talk

Major News Events

Correction to Precious Metals Market Talk on April 9

13 kwi 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 kwi 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-35.73% downside

12 Months Forecast

Average 5 USD -35.73%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

154 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.